Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
136.97
+0.09 (+0.07%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
2 No-Brainer Healthcare Stocks to Buy With $1,000
Today 9:30 EDT
There are no certainties in equity markets, but these stocks look highly likely to deliver outsized returns.
Via
The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
August 23, 2024
RedHill's Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results
Via
News Direct
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
August 23, 2024
Ozempic remains on top in the GLP-1 drug market -- but for how long?
Via
The Motley Fool
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
August 23, 2024
Vertex Pharmaceuticals has a lot going for it.
Via
The Motley Fool
What the Options Market Tells Us About Novo Nordisk
August 22, 2024
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,900 Today
August 20, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Novo Nordisk Through 8 Analysts
August 19, 2024
Via
Benzinga
Wegovy Now Available Through Sesame's $249 Monthly Compounded Program Despite Supply Shortages
August 21, 2024
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provides a $249 monthly alternative to expensive obesity treatments.
Via
Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong bullish...
Via
Benzinga
Topics
Economy
Exposures
Supply Chain
Eli Lilly Stock Could Soar to $1,150, According to a Wall Street Analyst. Is It a Buy at Around $945?
August 21, 2024
The Big Pharma stock is up by more than 50% in 2024, but investment-bank analysts think it has more room to run.
Via
The Motley Fool
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increased rate of suicidal thoughts after analyzing World Health Organization...
Via
Benzinga
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
August 19, 2024
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities...
Via
Benzinga
Unpacking the Latest Options Trading Trends in Novo Nordisk
August 15, 2024
Via
Benzinga
Telehealth Firm Hims & Hers Health Rides High On Demand for Copycat Weight Loss Drugs Amid Supply Shortages
August 19, 2024
Hims & Hers Health has seen its stock rise over 120% due to soaring demand for its affordable compounded GLP-1 weight-loss drugs, despite legal battles and safety concerns surrounding its...
Via
Benzinga
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
August 19, 2024
Impediments to growth are melting away while new opportunities begin to rise.
Via
The Motley Fool
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
August 18, 2024
Eli Lilly has a lot going for it.
Via
The Motley Fool
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
August 18, 2024
Should Novo Nordisk and Eli Lilly investors be worried about Roche?
Via
The Motley Fool
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
August 18, 2024
This list of top-selling drugs could look drastically different in a few years.
Via
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Buy?
August 17, 2024
The biotech could be worth a lot more in 10 years.
Via
The Motley Fool
3 Fantastic Growth Stocks to Buy in August
August 17, 2024
These stocks should keep up their winning ways.
Via
The Motley Fool
Could Viking Therapeutics Become the Next Novo Nordisk?
August 17, 2024
Given this biotech's ascent, its odds of becoming a giant are better than most.
Via
The Motley Fool
Doctors Struggle to Secure Medicare Coverage for Heart Patients on Novo Nordisk's Wegovy
August 16, 2024
Medicare patients struggle to access Novo Nordisk's Wegovy for heart disease treatment despite new guidelines, with many plans still denying coverage, highlighting challenges in the U.S. healthcare...
Via
Benzinga
Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market
August 16, 2024
Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while...
Via
Benzinga
Prediction: Up 74% So Far This Year, This Weight Loss Stock Is About to Crater
August 16, 2024
A small telemedicine company just entered the weight loss race.
Via
The Motley Fool
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
August 15, 2024
There are a number of pharmaceutical companies looking to make waves in the weight loss market.
Via
The Motley Fool
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
The unveiled prices follow months of back-and-forth negotiation between the government and the companies.
Via
Investor's Business Daily
Is Novo Nordisk's Earnings Miss a Cause for Concern for Investors?
August 15, 2024
Novo Nordisk still expects to see a lot more growth in the second half.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
August 14, 2024
Eli Lilly issues cease-and-desist letters to healthcare providers, demanding they stop promoting compounded weight-loss drugs as supply improves. The move has sparked tension, with providers arguing...
Via
Benzinga
Exposures
Product Safety
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
August 14, 2024
On Thursday, Eli Lilly and Company (NYSE: LLY) reported its second quarter results, smashing estimates fueled by the popularity of its blockbuster diabetes drug Mounjaro and weight loss injection...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.